药石科技跌2.01%，成交额1.90亿元，主力资金净流出1650.23万元

Core Viewpoint - The stock of Yaoshi Technology has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.33%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Yaoshi Technology reported a revenue of 920 million yuan for the first half of 2025, reflecting a year-on-year growth of 23.48%. However, the net profit attributable to shareholders decreased by 26.54% to 72.5 million yuan [2]. - Cumulatively, since its A-share listing, Yaoshi Technology has distributed a total of 231 million yuan in dividends, with 137 million yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Yaoshi Technology as of September 30 is 46,500, a decrease of 2.94% from the previous period. The average number of circulating shares per person increased by 3.03% to 4,363 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.1466 million shares, a decrease of 1.2259 million shares from the previous period, while Southern CSI 1000 ETF increased its holdings by 278,200 shares to 1.4751 million shares [3]. Business Overview - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is primarily engaged in the research, development, production, and sales of drug molecular building blocks. Its revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in synthetic biology, biopharmaceuticals, innovative drugs, and cancer drugs [1].